Analyst: Eli Lilly price drop is a sign of competitive US insulin market

Eli Lilly has lowered the price of its cheapest insulin products in the US, and according to an analyst, this is a clear expression of the intense competition on the market.
Photo: MIKE SEGAR/REUTERS / X90033
Photo: MIKE SEGAR/REUTERS / X90033
BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN

The US-based pharmaceutical company Eli Lilly's price reduction on its already cheapest insulin products signifies the tough competition on the US insulin market, in which the company is fighting for its market share with, for instance, Denmark's Novo Nordisk.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading